insufficienza respiratoria
DESCRIPTION
Insufficienza Respiratoria. Andrea Vianello Fisiopatologia e Terapia Intensiva Respiratoria Ospedale – Università di Padova. VCO 2. Airway narrowing & obstruction. Airway Inflammation. Frictional WOB. Shortened muscles curvature. Auto- PEEP. Elastic WOB. Gas trapping. - PowerPoint PPT PresentationTRANSCRIPT
![Page 1: Insufficienza Respiratoria](https://reader035.vdocument.in/reader035/viewer/2022062217/5681451c550346895db1dd98/html5/thumbnails/1.jpg)
Insufficienza Respiratoria
Andrea VianelloAndrea VianelloFisiopatologia e Terapia Intensiva RespiratoriaFisiopatologia e Terapia Intensiva Respiratoria
Ospedale – Università di PadovaOspedale – Università di Padova
![Page 2: Insufficienza Respiratoria](https://reader035.vdocument.in/reader035/viewer/2022062217/5681451c550346895db1dd98/html5/thumbnails/2.jpg)
AirwayInflammatio
n
Airwaynarrowing &obstruction
Shortened
muscles curvatur
e
FrictionalWOB
musclestrength
VT
PaCO2
pH PaO2
Gastrapping
Auto-PEEP
VCO2
VE
ElasticWOB
VA
![Page 3: Insufficienza Respiratoria](https://reader035.vdocument.in/reader035/viewer/2022062217/5681451c550346895db1dd98/html5/thumbnails/3.jpg)
AirwayInflammatio
n
Airwaynarrowing &obstruction
Shortened
muscles curvatur
e
FrictionalWOB
musclestrength
VT
PaCO2
pH PaO2
Gastrapping
Auto-PEEP
VCO2
VE
ElasticWOB
VA
Steroids
Abx
BDs
usa i farmaci e bene !usa i farmaci e bene !usa i farmaci e bene !usa i farmaci e bene !
Teophylline
![Page 4: Insufficienza Respiratoria](https://reader035.vdocument.in/reader035/viewer/2022062217/5681451c550346895db1dd98/html5/thumbnails/4.jpg)
AirwayInflammatio
n
Airwaynarrowing &obstruction
Shortened
muscles curvatur
e
FrictionalWOB
musclestrength
VT
PaCO2
pH PaO2
Gastrapping
Auto-PEEP
VCO2
VE
ElasticWOB
VA
PEEP
MV
Steroids
Abx
MVMV
BDs
usa i farmaci e bene !usa i farmaci e bene !usa i farmaci e bene !usa i farmaci e bene !
Teophylline
![Page 5: Insufficienza Respiratoria](https://reader035.vdocument.in/reader035/viewer/2022062217/5681451c550346895db1dd98/html5/thumbnails/5.jpg)
Non-Invasive
Ventilation““a form of a form of ventilatory ventilatory support that support that avoids airway avoids airway invasion”invasion”
Hill et al Crit Care Med 2007; 35:2402-7Hill et al Crit Care Med 2007; 35:2402-7
![Page 6: Insufficienza Respiratoria](https://reader035.vdocument.in/reader035/viewer/2022062217/5681451c550346895db1dd98/html5/thumbnails/6.jpg)
NIV VS TRATTAMENTO STANDARD
Keenan S et al
![Page 7: Insufficienza Respiratoria](https://reader035.vdocument.in/reader035/viewer/2022062217/5681451c550346895db1dd98/html5/thumbnails/7.jpg)
NIV VS TRATTAMENTO STANDARD
Keenan S et al
![Page 8: Insufficienza Respiratoria](https://reader035.vdocument.in/reader035/viewer/2022062217/5681451c550346895db1dd98/html5/thumbnails/8.jpg)
NIV - Meta-analysis (n=8)
• NPPV resulted in – decreased mortality (RR 0.41; 95% CI 0.26, 0.64), – decreased need for ETI (RR 0.42; 95%CI 0.31, 0.59)
• Greater improvements within 1 hour in – pH (WMD 0.03; 95%CI 0.02, 0.04),
– PaCO2 (WMD -0.40 kPa; 95%CI -0.78, -0.03),
– RR (WMD –3.08 bpm; 95%CI –4.26, -1.89). • Complications associated with treatment (RR 0.32;
95%CI 0.18, 0.56) and length of hospital stay were also reduced with NPPV (WMD –3.24 days; 95%CI –4.42, -2.06)
Lightowler, Elliott, Wedzicha & Ram BMJ 2003; 326:185Lightowler, Elliott, Wedzicha & Ram BMJ 2003; 326:185
![Page 9: Insufficienza Respiratoria](https://reader035.vdocument.in/reader035/viewer/2022062217/5681451c550346895db1dd98/html5/thumbnails/9.jpg)
49 pazienti con IRA in BPCO dopo fallimento terapia medica, pH 49 pazienti con IRA in BPCO dopo fallimento terapia medica, pH 7.27.2
• Simili durata di permanenza in ICU, durata VM, complicanze Simili durata di permanenza in ICU, durata VM, complicanze generali, mortalità in ICU, e mortalità in ospedalegenerali, mortalità in ICU, e mortalità in ospedale
• con NIV 48% evitano ETI, sopravvivono con permanenza in ICUcon NIV 48% evitano ETI, sopravvivono con permanenza in ICU inferioreinferiore vs pazienti VM invasiva (P=0.02) vs pazienti VM invasiva (P=0.02)
• A 1 anno: NIV inferiore riospedalizzazione (65% vs 100% A 1 anno: NIV inferiore riospedalizzazione (65% vs 100% P=0.016) e minor frequenza di riutilizzo supplemento di P=0.016) e minor frequenza di riutilizzo supplemento di ossigeno (0% vs 36%) ossigeno (0% vs 36%)
![Page 10: Insufficienza Respiratoria](https://reader035.vdocument.in/reader035/viewer/2022062217/5681451c550346895db1dd98/html5/thumbnails/10.jpg)
Studio caso-controllo: 64 paz. con IRA trattati con NIV pH = 7.18Studio caso-controllo: 64 paz. con IRA trattati con NIV pH = 7.18
• 40/64 (62%) fallimento NIV (RR con NIV - 38%) 40/64 (62%) fallimento NIV (RR con NIV - 38%)
• Simili mortalità in ICU, e mortalità in ospedale; durata di Simili mortalità in ICU, e mortalità in ospedale; durata di permanenza in ICU e post ICU, ma:permanenza in ICU e post ICU, ma:
• Inferiori complicanze (P=0.01) e probabilità di rimanenere in Inferiori complicanze (P=0.01) e probabilità di rimanenere in VM (P=0.056)VM (P=0.056)
• Se NIV efficace (24/64 = 38%) Se NIV efficace (24/64 = 38%) migliore sopravvivenza e ridotta migliore sopravvivenza e ridotta permanenza in ICUpermanenza in ICU vs pazienti VM invasiva vs pazienti VM invasiva
![Page 11: Insufficienza Respiratoria](https://reader035.vdocument.in/reader035/viewer/2022062217/5681451c550346895db1dd98/html5/thumbnails/11.jpg)
NIV: Change in practice over time
• 1992-1996 (mean pH = 7.25+/-0.07) 1997-1999 (7.20+/-0.08; P<0.001).
• > 1997 - risk of failure pH <7.25 three fold lower than in 1992-1996.
• > 1997 ARF with a pH >7.28 were treated in Medical Ward (20% vs 60%).
• Daily cost per patient treated with NIV (€558+/-8 vs €470+/-14,P<0.01)
Carlucci et al Intensive Care Med 2003; 3:419-25
![Page 12: Insufficienza Respiratoria](https://reader035.vdocument.in/reader035/viewer/2022062217/5681451c550346895db1dd98/html5/thumbnails/12.jpg)
Epidemiology•Rationale: evidence supporting use
of NIV varies widely for different causes of ARF.
•Population: 11,659,668 cases of ARF from the Nationwide Inpatient Sample during years 2000 to 2009;
•Objectives: To compare utilization trends and outcomes associated with NIV in patients with and without COPD.
![Page 13: Insufficienza Respiratoria](https://reader035.vdocument.in/reader035/viewer/2022062217/5681451c550346895db1dd98/html5/thumbnails/13.jpg)
![Page 14: Insufficienza Respiratoria](https://reader035.vdocument.in/reader035/viewer/2022062217/5681451c550346895db1dd98/html5/thumbnails/14.jpg)
•Rationale: The patterns and outcomes of NIV use in patients hospitalized for AECOPD nationwide are unknown.
•Population: 7,511,267 admissions for acute AE occurred from 1998 to 2008;
•Objectives: To determine the prevalence and trends of NIV in AECOPD.
![Page 15: Insufficienza Respiratoria](https://reader035.vdocument.in/reader035/viewer/2022062217/5681451c550346895db1dd98/html5/thumbnails/15.jpg)
Use of NIPPV or IMV as first-line respiratory Use of NIPPV or IMV as first-line respiratory support in patients hospitalized with support in patients hospitalized with
AECOPDAECOPD
![Page 16: Insufficienza Respiratoria](https://reader035.vdocument.in/reader035/viewer/2022062217/5681451c550346895db1dd98/html5/thumbnails/16.jpg)
Joint BTS/RCP London/Intensive Care Society Guidelines. NIV in COPD. Oct 2008
![Page 17: Insufficienza Respiratoria](https://reader035.vdocument.in/reader035/viewer/2022062217/5681451c550346895db1dd98/html5/thumbnails/17.jpg)
When to use Non-Invasive VentilationWhen to use Non-Invasive Ventilation
![Page 18: Insufficienza Respiratoria](https://reader035.vdocument.in/reader035/viewer/2022062217/5681451c550346895db1dd98/html5/thumbnails/18.jpg)
Goals of NIVcan they be reached?
NIV is time consuming, needs proper equipment, enough staff with sufficient expertise.
time technical equipmentstaff expertise
predict success of NIV
![Page 19: Insufficienza Respiratoria](https://reader035.vdocument.in/reader035/viewer/2022062217/5681451c550346895db1dd98/html5/thumbnails/19.jpg)
Eur Respir J 2002; 19: 1159–66
![Page 20: Insufficienza Respiratoria](https://reader035.vdocument.in/reader035/viewer/2022062217/5681451c550346895db1dd98/html5/thumbnails/20.jpg)
Definition of the three levels of care
European Task Force on Respiratory Intermediate Care Survey Corrado et al, ERJ 2002;20:1343-50
![Page 21: Insufficienza Respiratoria](https://reader035.vdocument.in/reader035/viewer/2022062217/5681451c550346895db1dd98/html5/thumbnails/21.jpg)
Appropriatezza di utilizzo della Ventilazione Non-Appropriatezza di utilizzo della Ventilazione Non-Invasiva in ambito pneumologico nell’assistenza ai Invasiva in ambito pneumologico nell’assistenza ai pazienti con BroncoPneumopatia Cronica Ostruttiva pazienti con BroncoPneumopatia Cronica Ostruttiva
in fase acuta.in fase acuta.
Appropriatezza di utilizzo della Ventilazione Non-Appropriatezza di utilizzo della Ventilazione Non-Invasiva in ambito pneumologico nell’assistenza ai Invasiva in ambito pneumologico nell’assistenza ai pazienti con BroncoPneumopatia Cronica Ostruttiva pazienti con BroncoPneumopatia Cronica Ostruttiva
in fase acuta.in fase acuta.
![Page 22: Insufficienza Respiratoria](https://reader035.vdocument.in/reader035/viewer/2022062217/5681451c550346895db1dd98/html5/thumbnails/22.jpg)
Rate of NIV failure is extremely different according to study design,
severity of illness and level of monitoring
![Page 23: Insufficienza Respiratoria](https://reader035.vdocument.in/reader035/viewer/2022062217/5681451c550346895db1dd98/html5/thumbnails/23.jpg)
Overall NIV failure: 16.3%
Sixty-two RCTs including a total of 5870 patients
![Page 24: Insufficienza Respiratoria](https://reader035.vdocument.in/reader035/viewer/2022062217/5681451c550346895db1dd98/html5/thumbnails/24.jpg)
• Evaluation of all 449 patients receiving NPPV for a 1-yr period for acute or acute on chronic RF– CPE (n=97) – AECOPD (n=87)– non-COPD acute hypercapnic
RF (n=35) – postextubation RF (n=95)– acute hypoxemic RF (n=144)
• Intubation rate was 18%, 24%, 38%, 40%, and 60%, respectively
• Hospital mortality for patients with acute hypoxemic RF who failed NPPV was 64%
Schettino G. Crit Care Med 2008; 36:441-7
NIV – Real Life
![Page 25: Insufficienza Respiratoria](https://reader035.vdocument.in/reader035/viewer/2022062217/5681451c550346895db1dd98/html5/thumbnails/25.jpg)
The percentage of patients transitioned from NIV to IMV ≈ 5% and did not increase from 1998 to 2008
![Page 26: Insufficienza Respiratoria](https://reader035.vdocument.in/reader035/viewer/2022062217/5681451c550346895db1dd98/html5/thumbnails/26.jpg)
Reasons for low rate of IMV use after NPPV, compared to clinical
trial:
• End of life decision to not accept IMV
• Patients died before IMV could be started
• Good selection of appropriate patients
![Page 27: Insufficienza Respiratoria](https://reader035.vdocument.in/reader035/viewer/2022062217/5681451c550346895db1dd98/html5/thumbnails/27.jpg)
• High mortality rate (≈30%) ;↑ over time
• OR for death:1.63, compared to those initially on IMV
• ↑hospital stay
![Page 28: Insufficienza Respiratoria](https://reader035.vdocument.in/reader035/viewer/2022062217/5681451c550346895db1dd98/html5/thumbnails/28.jpg)
• Nearly one third of patients for whom there is the best evidence base for NIV did not receive it– Admission pH < 7.26: 66% received NIV
compared to 34% pH 7.26 to 7.34. – Similar lowest pH
• Significant proportion had a metabolic acidosis• Hospital mortality was 25% (270/1077) for
patients receiving NIV but 39% (86/219) for those with late onset acidosis
• “The audit raises concerns that challenge the respiratory community to lead appropriate clinical improvements across the acute sector
![Page 29: Insufficienza Respiratoria](https://reader035.vdocument.in/reader035/viewer/2022062217/5681451c550346895db1dd98/html5/thumbnails/29.jpg)
Reasons for high mortality rate in patients transitioned to IMV
• Increased use of NIPPV in patients difficult to ventilate?
• Continuation of NIPPV despite a lack of early improvement?
![Page 30: Insufficienza Respiratoria](https://reader035.vdocument.in/reader035/viewer/2022062217/5681451c550346895db1dd98/html5/thumbnails/30.jpg)
Aetiology of NIV failureA. Failure to adequately
ventilate/oxygenateA. Delayed NIV treatment
B. Inappropriate ventilatory technique
C. Patient’s clinical condition
B. Dependence on non-invasive
support
Lack of improvement of acute illness
C. Complications
![Page 31: Insufficienza Respiratoria](https://reader035.vdocument.in/reader035/viewer/2022062217/5681451c550346895db1dd98/html5/thumbnails/31.jpg)
NIV failure is predicted by:- Advanced age- High acuity illness on admission (i.e. SAPS-II
>34)- Acute respiratory distress syndrome- Community-acquired pneumonia with or without
sepsis- Multi-organ system failure
![Page 32: Insufficienza Respiratoria](https://reader035.vdocument.in/reader035/viewer/2022062217/5681451c550346895db1dd98/html5/thumbnails/32.jpg)
![Page 33: Insufficienza Respiratoria](https://reader035.vdocument.in/reader035/viewer/2022062217/5681451c550346895db1dd98/html5/thumbnails/33.jpg)
Retrospective analysis 59 episodes of ARF in 47 COPD
patients• NIV success: 46• NIV failure: 13
Predictors for NIV failure:• Higher PaCO2 at admission• Worse functional condition• Reduced treatment compliance
• Pneumonia
NIV in acute COPD: correlates for success
Ambrosino N, Thorax 1995;50:755-7Ambrosino N, Thorax 1995;50:755-7
NIV failure
Other Pneumonia
%
0
20
40
60
n=8
p=0.019n=5
![Page 34: Insufficienza Respiratoria](https://reader035.vdocument.in/reader035/viewer/2022062217/5681451c550346895db1dd98/html5/thumbnails/34.jpg)
NIV complicationsComplication Incidenc
e (%)
MajorAspiration pneumonia <5
Haemodinamyc collapse Infrequent
Barotrauma Rare
MinorNoise 50-10
CO2 rebreathing 50-100
Discomfort 30-50
Claustrophobia 5-20
Nasal skin lesions 2-50
![Page 35: Insufficienza Respiratoria](https://reader035.vdocument.in/reader035/viewer/2022062217/5681451c550346895db1dd98/html5/thumbnails/35.jpg)
Mask selection - a crucial issue!
Noise (50-100%)Noise (50-100%)
COCO22 rebreathing (50-100%) rebreathing (50-100%)
Leak/Discomfort (30-50%)Leak/Discomfort (30-50%)
Claustrophobia (5-20%)Claustrophobia (5-20%)
Nasal skin lesions (2-50%)Nasal skin lesions (2-50%)
![Page 36: Insufficienza Respiratoria](https://reader035.vdocument.in/reader035/viewer/2022062217/5681451c550346895db1dd98/html5/thumbnails/36.jpg)
• Respiratory arrest• Inability to tolerate the device, because of
claustrophobia, agitation or uncooperativeness• Inability to protect the airway, due to
swallowing impairment• Excessive secretions not sufficiently
managed by clearance techniques• Recent upper airway surgery
NIV should not be used in:
![Page 37: Insufficienza Respiratoria](https://reader035.vdocument.in/reader035/viewer/2022062217/5681451c550346895db1dd98/html5/thumbnails/37.jpg)
Transition to IMV: when is in the interest of a patient?
• Hospital mortality: 64% (Schettino, 2008)• Mortality rate: 30%; prolonged
hospitalization (Chandra, 2011)• Great hospital mortality (Walkey, 2013)
![Page 38: Insufficienza Respiratoria](https://reader035.vdocument.in/reader035/viewer/2022062217/5681451c550346895db1dd98/html5/thumbnails/38.jpg)
Transition to IMV(personal experience, 2011-2013)
Number of subjects 62
Age (mean ± SD) , yrs 65.4±19.3
Gender (males, females) 26, 36
Ineffective NIV, n (%) Severe hypercapnia Severe hypoxemia
52 (83.8)25 (42.4)21 (35.6)
Dependence on NIV, n (%)
8 (13.3)
NIV complication, n (%) 2 (3.4)
Tracheotomy, n (%) 16 (28.8)
Outcome , n (%) Died during hosp Discharged from hosp
41 (66.1)21 (33.9)
![Page 39: Insufficienza Respiratoria](https://reader035.vdocument.in/reader035/viewer/2022062217/5681451c550346895db1dd98/html5/thumbnails/39.jpg)
Kaplan-Meier function of overall survival
Median survival:46 days
(95% CI, 43 to 162)
![Page 40: Insufficienza Respiratoria](https://reader035.vdocument.in/reader035/viewer/2022062217/5681451c550346895db1dd98/html5/thumbnails/40.jpg)
Kaplan-Meier function of survival according to baseline condition
Mean survival:NM/CW = 305.58±36.9COPD = 53.90±7.3 ILD = 31.13±7.8
] p=0.0176] p<0.0001
![Page 41: Insufficienza Respiratoria](https://reader035.vdocument.in/reader035/viewer/2022062217/5681451c550346895db1dd98/html5/thumbnails/41.jpg)
Kaplan-Meier function of survival for dichotomus age (50 and >50)
Median survival:50 = 380.0 d (95%CI, 15.0 to n.c.)>50 = 45.0 d (95%CI,24.0 to 54.0)
] p=0.0071
![Page 42: Insufficienza Respiratoria](https://reader035.vdocument.in/reader035/viewer/2022062217/5681451c550346895db1dd98/html5/thumbnails/42.jpg)
Remarks
• Mortality rate among patients transitioned to IMV is very high;
• The outcome of patients with ILD is extremely poor.
Should IPF/COPD patients be excluded from IMV after failing a NIV trial?
![Page 43: Insufficienza Respiratoria](https://reader035.vdocument.in/reader035/viewer/2022062217/5681451c550346895db1dd98/html5/thumbnails/43.jpg)
Use of a novel veno-venous extracorporeal carbon dioxide removal system as an alternative to endotracheal intubation in a lung transplant
candidate with acute respiratory failure.
Submitted to Respiratory Care
![Page 44: Insufficienza Respiratoria](https://reader035.vdocument.in/reader035/viewer/2022062217/5681451c550346895db1dd98/html5/thumbnails/44.jpg)
![Page 45: Insufficienza Respiratoria](https://reader035.vdocument.in/reader035/viewer/2022062217/5681451c550346895db1dd98/html5/thumbnails/45.jpg)
NIV in AECOPD: conclusions• Confirm and reinforce the routine use
of NIV, however:
• The problem of transitioning from NIV to IMV: may not be in the interest of patients!
• Suggest caution with NIV among patients at high risk of failure